ATLANTA – September 27, 2018
Coyne Scientific, LLC (Atlanta, GA) announced today that it will offer the world’s first commercially-available “Clinical Trials in a Dish” at the Safety Pharmacology Society’s 2018 Annual Meeting, which runs from October 1-3 in Washington, DC.
What exactly does the company mean by “Clinical Trials In A Dish”? According to Chief Executive Officer Kevin P. Coyne, it means that “Coyne Scientific conducts hiPSC-derived-cardiomyocyte-based assays using representative cohorts of human donors to assess the cardiac safety and toxicity of drugs across a target population, in order to detect the presence and incidence of drug-responders prior to actual clinical trials”. Added President Shawn T. Coyne: “Our unique platform challenges the current rules of drug development by introducing ‘clinical’ methodologies to the ‘preclinical’ environment. This can generate valuable insights that current preclinical testing approaches don’t deliver, helping our clients to reduce attrition while allowing safe drugs to proceed and succeed in clinical development”.
After five years of research, including extensive proof-of-concept testing and a joint development project with a “Top 5” global pharmaceutical company, Coyne Scientific recently began offering its services on a commercial basis from its new, highly-automated, 6,500 sq, ft. lab and office facility located in Atlanta, Georgia, USA.
Anyone attending the SPS 2018 Annual Meeting is invited to learn more about Coyne Scientific by:
o Visiting Booth #121 during Exhibit Hall hours (from 9:00am to 5:00pm on Monday, October 1 and Tuesday, October 2) and meeting with CEO Kevin Coyne, President Shawn Coyne, or Senior Director of Data Science & Operations Eli Fine.
o Viewing Poster #165, titled “Clinical Trials In A Dish: Different Inter-Individual Drug Responses for Calcium Handling and Electrophysiology in a Cohort of hiPSC-Derived Cardiomyocytes”.
For more information, please contact Shawn Coyne at email@example.com.
* * *
ABOUT COYNE SCIENTIFIC, LLC
Coyne Scientific is a biotech services company that conducts in vitro safety and toxicity testing on pharmaceutical compounds. We use human stem cell-based models to demonstrate the range and distribution of toxicity reactions to compounds across a population as a result of that population’s genetic diversity. We can help clients dramatically reduce drug development costs through early identification of compounds that may negatively affect a portion of clinical trial participants despite appearing to be safe to the “average” human. We can also help improve the safety of drugs in cases where large clinical trials are infeasible, such as in the entry of drugs into small national markets with genetically-distinct populations.
For more information, please contact Shawn T. Coyne, President, at firstname.lastname@example.org.